|
|
| R & D |
| Allermed is a leader in the development of biologics that induce a cellular immune response. Delayed-type skin test antigens of Coccidioides immitis and Leishmania tropica are in phase II and Phase III clinical trials. Clinical trials are being conducted on the treatment of Verruca vulgaris by activating an immune response intralesionally with a biologic product derived from the yeast Candida albicans. |
Testimonial
"I was very happy to have worked with Allermed on the development of spherule-based coccidioidin. The return of this product to the market will provide clinicians with a valuable tool in the diagnosis and management of coccidioidomycosis."
Neil M. Ampel, M.D.
Professor of Medicine
University of Arizona |
|
| |
|
